On Tuesday, Summit Therapeutics Inc (NASDAQ: SMMT) opened lower -4.09% from the last session, before settling in for the closing price of $25.4. Price fluctuations for SMMT have ranged from $8.39 to $36.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.52% over the last five years. Company’s average yearly earnings per share was noted -28.39% at the time writing. With a float of $111.44 million, this company’s outstanding shares have now reached $741.61 million.
The firm has a total of 159 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Summit Therapeutics Inc (SMMT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Summit Therapeutics Inc is 84.99%, while institutional ownership is 13.21%.
Summit Therapeutics Inc (SMMT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -21.52% during the next five years compared to -10.52% drop over the previous five years of trading.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Check out the current performance indicators for Summit Therapeutics Inc (SMMT). In the past quarter, the stock posted a quick ratio of 10.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Analysing the last 5-days average volume posted by the [Summit Therapeutics Inc, SMMT], we can find that recorded value of 2.86 million was lower than the volume posted last year of 3.78 million. As of the previous 9 days, the stock’s Stochastic %D was 76.06%.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 41.25%, which indicates a significant decrease from 67.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.54 in the past 14 days, which was lower than the 1.91 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.82, while its 200-day Moving Average is $20.93. Now, the first resistance to watch is $25.24. This is followed by the second major resistance level at $26.13. The third major resistance level sits at $26.71. If the price goes on to break the first support level at $23.78, it is likely to go to the next support level at $23.20. Should the price break the second support level, the third support level stands at $22.32.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are currently 742,666K shares outstanding in the company with a market cap of 18.09 billion. Presently, the company’s annual sales total 0 K according to its annual income of -221,320 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -62,910 K.
